NovaBay Pharmaceuticals Receives Approval for Distribution of Avenova in Australia
September 24 2019 - 06:50AM
Business Wire
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a
biopharmaceutical company focusing on commercializing Avenova® for
the domestic eye care market, announces that it has received
approval for the distribution of Avenova from the Australian
Government Department of Health and has been provided an Australian
Register of Therapeutic Goods Certificate.
“We are pleased to receive approval to market Avenova in
Australia and are planning to engage a distributor in the near
term,” said Justin Hall, NovaBay president and CEO. “This marks
another step forward in our goal to increase the availability of
Avenova to dry eye sufferers. Avenova is the only commercially
available pure hypochlorous acid formulation and we believe it is
the best product to treat the chronic bacterial infections that
affect approximately 85% of all dry eye sufferers and we are
delighted we can make it available to Australians who struggle with
this affliction. Avenova is free from the bleach impurities found
in other hypochlorous products, is soothing to the eye, and is safe
and effective for long-term use.”
Prescription medicines and over-the-counter medicines which meet
Australian standards of quality, safety and efficacy are included
on the Australian Register of Therapeutic Goods.
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company
focusing on commercializing and developing its non-antibiotic
anti-infective products to address the unmet therapeutic needs of
the global, topical anti-infective market with its two distinct
product categories: the NEUTROX® family of products and the
AGANOCIDE® compounds. The Neutrox family of products includes
AVENOVA® for the eye care market, NEUTROPHASE® for wound care
market, and CELLERX® for the aesthetic dermatology market. The
Aganocide compounds, still under development, have target
applications in the dermatology and urology markets.
Forward-Looking Statements
This release contains forward-looking statements that are based
upon management’s current expectations, assumptions, estimates,
projections and beliefs. These statements include, but are not
limited to, statements regarding our business strategies and future
focus, the composition of our Board of Directors, and generally the
Company’s expected future financial results. These statements
involve known and unknown risks, uncertainties and other factors
that may cause actual results or achievements to be materially
different and adverse from those expressed in or implied by the
forward-looking statements. Factors that might cause or contribute
to such differences include, but are not limited to, risks and
uncertainties relating to the size of the potential market for our
products, improving sales rep productivity and product
distribution, obtaining adequate insurance reimbursement, and any
potential regulatory problems. Other risks relating to NovaBay’s
business, including risks that could cause results to differ
materially from those projected in the forward-looking statements
in this press release, are detailed in NovaBay’s latest Form 10-Q/K
filings with the Securities and Exchange Commission, especially
under the heading “Risk Factors.” The forward-looking statements in
this release speak only as of this date, and NovaBay disclaims any
intent or obligation to revise or update publicly any
forward-looking statement except as required by law.
Socialize and Stay informed on
NovaBay’s progress Like us on Facebook Follow
us on Twitter Connect with NovaBay on LinkedIn Visit
NovaBay’s Website
Avenova Purchasing
Information For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com www.Avenova.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190924005330/en/
NovaBay Contact Justin Hall
President and Chief Executive Officer 510-899-8800
jhall@novabay.com
Investor Contact LHA
Investor Relations Jody Cain 310-691-7100 jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Feb 2024 to Mar 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Mar 2023 to Mar 2024